Alopecia Universalis With IL-12-RB1 and STAT4 Mutations Effectively Treated With Upadacitinib

    August 2024 in “ JAAD Case Reports ”
    Emily R. Gordon, Luke Horton, Natasha Atanaskova Mesinkovska
    Studysummary This article reviews the current FDA-approved treatments for severe pediatric alopecia areata, including the use of Janus kinase inhibitors, but reports no new clinical findings.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jaadcasereports.org →
    Discuss this study in the Community →

    Research cited in this study 6

    1. Upadacitinib for Successful Treatment of Alopecia Universalis in a Child: A Case Report and Literature Review Acta Dermato Venereologica · 2023
    2. Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib: A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata Dermatology and therapy · 2023
    3. Impact of Pediatric Alopecia Areata on Quality of Life of Patients and Their Family Members: A Nationwide Multicenter Questionnaire Study Annals of Dermatology · 2022
    4. An Excellent Response to Tofacitinib in a Brazilian Adolescent Patient with Alopecia Areata: A Case Report and Review of the Literature Clinical Case Reports · 2019
    5. Tofacitinib Therapy for Children with Severe Alopecia Areata Journal of the American Academy of Dermatology · 2019
    6. Tofacitinib for the Treatment of Alopecia Areata in Preadolescent Children Journal of the American Academy of Dermatology · 2018

    Related research 1

    1. A Case Report of Verruca Vulgaris on Basis of Alopecia Areata Successfully Treated with Diphenylcyclopropenone International journal of trichology · 2017